Clinical Outcomes of Eradication of Helicobacter pylori in Nonulcer Dyspepsia in a Population with a High Prevalence of Infection: Results of a 12-Month Randomized, Double Blind, Placebo-Controlled Study
- 164 Downloads
Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.
Key Wordsdyspepsia Helicobacter pylori gastritis endoscopy gastrointestinal
Unable to display preview. Download preview PDF.
- 9.Blum AL, Talley NJ, O'Morain C, et al.: Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 339:1875–1881, 1998Google Scholar
- 16.Oliveira AMR, Rocha GA, Queiroz DMM, et al.: Prevalence of H. pylori infection in a population from the rural area of Araćcua'i, MG, Brazil. Rev Microbiol 30:59–61, 1999Google Scholar
- 18.Cunha RPA, Alves FP, Rocha AMC, et al.: Prevalence and risk factors associated with Helicobacter pylori infection in native populations from Brazilian Western Amazon. Trans Roy Soc Trop Med Hygiene 97:382–386, 2003Google Scholar
- 19.Talley NJ, Janssens J, Lauritsen K, et al.: Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 month follow-up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ 318:833–837, 1999Google Scholar
- 20.Talley NJ, Colin-Jones DG, Koch KI, et al.: Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 4:145–160, 1991Google Scholar
- 22.Tytgat GN: The Sydney System: endoscopic division. Endoscopic appearances in gastritis/duodenitis. J Gastroenterol Hepatol 6:223–234, 1991Google Scholar
- 23.Dixon MF, Genta RM, Yardley JH, et al.: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181, 1996Google Scholar
- 27.Streiner DL, Norman GR: Health Measurement Scales. 2nd ed. Oxford, Oxford Medical, 1995Google Scholar
- 29.Bruley DV, Flejou JF, Colin R, et al.: There are some benefits for eradicating Helicobacter pylori in patients with nonulcer dyspepsia. Aliment Pharmacol Ther 15:1177–1185, 2001Google Scholar
- 32.Laine L, Schoenfeld P, Fennerty MB: Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 134:361–369, 2001Google Scholar
- 33.Moayyedi P, Soo S, Deeks J, et al.: Systematic review and economic evaluation of Helicobacter pylori eradication treatment for nonulcer dyspepsia. Dyspepsia Review Group. BMJ 321:659–664, 2000Google Scholar